Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Rating of “Buy” by Brokerages

Posted by Francis Steltz on Jun 16th, 2026

Trevi Therapeutics, Inc. (NASDAQ:TRVI – Get Free Report) has earned an average rating of “Buy” from the twelve research firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, nine have issued a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $22.90.

Several research firms have recently weighed in on TRVI. HC Wainwright reiterated a “buy” rating and set a $21.00 target price on shares of Trevi Therapeutics in a research report on Wednesday, May 6th. JonesTrading decreased their target price on Trevi Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a research report on Thursday, March 19th. Needham & Company LLC reiterated a “buy” rating and set a $23.00 target price on shares of Trevi Therapeutics in a research report on Wednesday, May 20th. D. Boral Capital reiterated a “buy” rating and set a $19.00 target price on shares of Trevi Therapeutics in a research report on Friday, April 17th. Finally, Wall Street Zen downgraded Trevi Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th.

Read Our Latest Report on TRVI

Institutional Trading of Trevi Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in TRVI. Russell Investments Group Ltd. raised its holdings in shares of Trevi Therapeutics by 194.5% in the second quarter. Russell Investments Group Ltd. now owns 4,536 shares of the company’s stock valued at $25,000 after acquiring an additional 2,996 shares in the last quarter. KBC Group NV purchased a new position in Trevi Therapeutics in the first quarter valued at about $29,000. Hilton Head Capital Partners LLC purchased a new position in Trevi Therapeutics in the fourth quarter valued at about $40,000. Caitong International Asset Management Co. Ltd purchased a new position in Trevi Therapeutics in the fourth quarter valued at about $50,000. Finally, Strs Ohio purchased a new stake in shares of Trevi Therapeutics during the first quarter worth about $52,000. 95.76% of the stock is currently owned by institutional investors.

Trevi Therapeutics Stock Up 3.2%

NASDAQ TRVI opened at $14.66 on Thursday. The company has a fifty day moving average of $14.02 and a two-hundred day moving average of $12.52. The firm has a market capitalization of $2.08 billion, a price-to-earnings ratio of -45.81 and a beta of 1.04. Trevi Therapeutics has a 52 week low of $5.41 and a 52 week high of $16.12.

Trevi Therapeutics (NASDAQ:TRVI – Get Free Report) last released its earnings results on Tuesday, May 5th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.02). Equities research analysts anticipate that Trevi Therapeutics will post -0.47 EPS for the current year.

About Trevi Therapeutics

(Get Free Report)

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.